Shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $20.91, but opened at $21.46. ADMA Biologics shares last traded at $22.05, with a volume of 906,110 shares traded.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Get Our Latest Stock Report on ADMA
ADMA Biologics Price Performance
The stock has a market cap of $5.04 billion, a price-to-earnings ratio of 76.11 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a 50-day simple moving average of $18.26 and a two-hundred day simple moving average of $18.22.
Institutional Trading of ADMA Biologics
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. Vanguard Group Inc. increased its stake in shares of ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after purchasing an additional 80,302 shares during the last quarter. Geode Capital Management LLC increased its position in ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after buying an additional 50,399 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in ADMA Biologics by 16.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after buying an additional 643,661 shares during the period. Renaissance Technologies LLC lifted its position in shares of ADMA Biologics by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock valued at $64,654,000 after buying an additional 102,692 shares during the last quarter. Finally, Perpetual Ltd bought a new position in shares of ADMA Biologics during the 4th quarter worth approximately $62,300,000. 75.68% of the stock is owned by institutional investors.
ADMA Biologics Company Profile
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
